BSI 510
Alternative Names: BSI-510Latest Information Update: 06 Oct 2022
At a glance
- Originator Biosion
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immune checkpoint protein modulators; Macrophage stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 12 Sep 2022 Preclinical trials in Solid tumours in China (Parenteral) (Biosion pipeline, September 2022)
- 12 Sep 2022 Biosion plans to file an IND application with the US FDA for Solid tumours in 2023 (Biosion pipeline, September 2022)